


Sphene Equity Research Update Reaffirms "Buy" Rating on Vidac Pharma

Continued analyst endorsement underscores confidence in shareholder value and growth potential

LONDON, UNITED KINGDOM,
September 2, 2025 /EINPresswire.com/
-- Vidac Pharma Holdings Plc. a clinicalstage oncology company targeting
aberrant mitochondrial metabolism in
cancer, announced that Sphene Equity
Research has reaffirmed its "Buy"
recommendation on Vidac Pharma's
shares in its latest analyst report.



The updated report reflects continued confidence in Vidac's innovative approach to selectively targeting the hyper-glycolysis ("Warburg Effect") characteristic of cancer cells, caused by aberrant



Vidac is committed to advancing breakthrough therapies targeting the fundamental biology of cancer, and we are pleased to see growing recognition of cell metabolism as a key therapeutic frontier"

Dr. Max Herzberg

mitochondrial functions. Vidac Pharma's strategy is designed to re-open the VDAC1 channel, restoring the natural apoptosis (programmed cell death) signal that is blocked by excessive HK2 activity, and reducing high lactate production in the tumor microenvironment.

In reaffirming its recommendation, Sphene highlighted Vidac Pharma's differentiated position within oncology drug development and the potential of its clinical pipeline to address significant unmet medical needs.

The importance of targeting cell metabolism in cancer

continues to gain attention in both the scientific and financial communities. A recent article in news.financial reviewed new findings in this field and cited Roche, Novartis, and Vidac Pharma, through its mitochondrial-centered approach, as companies advancing work in this area. In addition, academic research such as the 2025 study by Lin et al. in Cancer Biology & Medicine underscores the therapeutic potential of interventions focused on mitochondrial function in cancer treatment.

Dr. Max Herzberg, CEO of Vidac Pharma, stated:

"We welcome Sphene Equity Research's continued endorsement of our strategy and pipeline. Vidac is committed to advancing breakthrough therapies targeting the fundamental biology of cancer, and we are pleased to see growing recognition of cell metabolism as a key therapeutic frontier."

Max Herzberg Vidac pharma Holding Plc +972 54-425-7381 email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/845004022

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.